retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports Lilly's triple agonist achieves 16.8%
Description
Holman, M
If you are coming from tirzepatide, our guide on retatrutide dosing after tirzepatide addresses the specific considerations for that transition
However, lifestyle changes are difficult to maintain over the long term [9]
These second order effects will become more far reaching as insurance coverage becomes wider for these drugs - this will be the differentiator between the risk/reward being better on the first-order beneficiaries (LLY and NVO) and the second-order plays like short bariatric surgery/sleep apnea/gyms/fast food & CPG
